Davis R M Inc. lifted its position in Celgene Co. (NASDAQ:CELG) by 15.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,549 shares of the biopharmaceutical company’s stock after buying an additional 480 shares during the quarter. Davis R M Inc.’s holdings in Celgene were worth $370,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in CELG. Beach Investment Management LLC. lifted its holdings in shares of Celgene by 1,935.3% in the second quarter. Beach Investment Management LLC. now owns 126,188 shares of the biopharmaceutical company’s stock worth $16,388,000 after buying an additional 119,988 shares in the last quarter. IMS Capital Management lifted its holdings in shares of Celgene by 3.8% in the second quarter. IMS Capital Management now owns 6,682 shares of the biopharmaceutical company’s stock worth $868,000 after buying an additional 247 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Celgene by 4.6% in the second quarter. Legal & General Group Plc now owns 3,751,507 shares of the biopharmaceutical company’s stock worth $487,210,000 after buying an additional 163,884 shares in the last quarter. Community Bank N.A. lifted its holdings in shares of Celgene by 1.3% in the second quarter. Community Bank N.A. now owns 4,037 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 50 shares in the last quarter. Finally, Allegis Investment Advisors LLC lifted its holdings in shares of Celgene by 13.0% in the second quarter. Allegis Investment Advisors LLC now owns 24,040 shares of the biopharmaceutical company’s stock worth $3,122,000 after buying an additional 2,772 shares in the last quarter. 78.10% of the stock is currently owned by hedge funds and other institutional investors.

Celgene Co. (NASDAQ:CELG) opened at $94.39 on Thursday. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99. Celgene Co. has a 52-week low of $88.32 and a 52-week high of $147.17. The company has a market cap of $71,000.00, a P/E ratio of 26.15, a price-to-earnings-growth ratio of 0.64 and a beta of 1.49.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm had revenue of $3.48 billion for the quarter, compared to analysts’ expectations of $3.46 billion. During the same quarter last year, the business earned $1.61 earnings per share. The business’s revenue was up 16.9% on a year-over-year basis. equities research analysts predict that Celgene Co. will post 7.68 EPS for the current fiscal year.

Celgene declared that its Board of Directors has initiated a stock repurchase program on Wednesday, February 14th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

In other news, insider Mark J. Alles bought 3,260 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were purchased at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the acquisition, the insider now owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.95% of the stock is currently owned by company insiders.

A number of brokerages have recently issued reports on CELG. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price target on the stock in a report on Thursday, January 25th. Mizuho set a $128.00 price target on shares of Celgene and gave the stock a “buy” rating in a report on Tuesday, December 26th. William Blair reissued an “outperform” rating on shares of Celgene in a report on Friday, October 20th. BTIG Research restated a “hold” rating on shares of Celgene in a research report on Tuesday, January 23rd. Finally, BidaskClub upgraded shares of Celgene from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Celgene currently has a consensus rating of “Buy” and a consensus price target of $130.35.

COPYRIGHT VIOLATION WARNING: “Celgene Co. (CELG) Stake Raised by Davis R M Inc.” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://theolympiareport.com/2018/02/15/celgene-co-celg-stake-raised-by-davis-r-m-inc.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.